CN Bio, a leading provider of Organ-on-a-chip Systems and solutions that accelerate drug discovery and development workflows, today announced the launch of its PhysioMimix® Bioavailability assay kit: Human 18. Harnessing the capabilities of the PhysioMimix Multi-organ System, the kit enhances lead optimization and preclinical testing pipelines, providing an all-in-one solution to generate predictive insights into human oral bioavailability, and better inform lead candidate selection.
Lenvatinib-Pembrolizumab Combo Misses Goal in First-Line HCC Trial
Combining lenvatinib (Lenvima) with an immune checkpoint inhibitor in the first-line setting for unresectable hepatocellular carcinoma (HCC) failed to significantly improve survival outcomes in an
December 14, 2023